CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
March 28, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
March 22, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces the Appointment of Chief Executive Officer
March 17, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
Cormedix Inc. Announces Resubmission of New Drug Application for DefenCath
February 28, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix to Participate in Upcoming January Conferences
January 04, 2022 08:00 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 09, 2021 16:05 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9
November 02, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI
October 20, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Executive Leadership Changes
October 04, 2021 16:01 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Regulatory Update
September 07, 2021 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...